# Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

> **NCT06824987** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 96 (estimated)

## Conditions studied

- APOL1-Mediated Kidney Disease

## Interventions

- **COMBINATION_PRODUCT:** AZD2373-Arm 1
- **COMBINATION_PRODUCT:** AZD2373-Arm 2
- **COMBINATION_PRODUCT:** Placebo
- **DEVICE:** APOL1 Genotyping Clinical Trial Assay

## Key facts

- **NCT ID:** NCT06824987
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-05
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824987, "Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06824987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*